Nwam LLC Bristol Myers Squibb CO Transaction History

Nwam LLC

$1.6 Billion
Q3 2024

A detailed history of Nwam LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Nwam LLC holds 17,922 shares of BMY stock, worth $1.04 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

17,922

Holding current value

$1.04 Million

% of portfolio

0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $710,786 - $927,463	17,922 New	17,922 $927,000
Q1 2024 May 09, 2024	SELL	$47.98 - $54.4 $9,404 - $10,662	-196 Reduced 1.04%	18,700 $1.01 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $44,650 - $53,279	921 Added 5.12%	18,896 $969,000
Q3 2023 Oct 31, 2023	SELL	$57.89 - $64.73 $477,534 - $533,957	-8,249 Reduced 31.46%	17,975 $1.04 Million
Q2 2023 Aug 09, 2023	SELL	$63.71 - $70.74 $2.02 Million - $2.24 Million	-31,718 Reduced 54.74%	26,224 $1.68 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $206,066 - $233,726	-3,136 Reduced 5.13%	57,942 $4.02 Million
Q4 2022 Feb 07, 2023	BUY	$68.48 - $81.09 $2.9 Million - $3.44 Million	42,402 Added 227.04%	61,078 $4.39 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $212 - $125,556	1,634 Added 9.59%	18,676 $1.33 Million
Q2 2022 Aug 10, 2022	SELL	$72.62 - $79.98 $111,253 - $122,529	-1,532 Reduced 8.25%	17,042 $1.3 Million
Q1 2022 May 12, 2022	BUY	$61.48 - $73.72 $11,189 - $13,417	182 Added 0.99%	18,574 $1.36 Million
Q4 2021 Feb 10, 2022	BUY	$53.63 - $62.52 $245,142 - $285,778	4,571 Added 33.07%	18,392 $1.15 Million
Q3 2021 Nov 03, 2021	BUY	$59.17 - $69.31 $123,369 - $144,511	2,085 Added 17.77%	13,821 $818,000
Q2 2021 Aug 04, 2021	SELL	$61.91 - $67.42 $42,779 - $46,587	-691 Reduced 5.56%	11,736 $784,000
Q1 2021 Apr 23, 2021	SELL	$59.34 - $66.74 $45,929 - $51,656	-774 Reduced 5.86%	12,427 $785,000
Q4 2020 Jan 22, 2021	BUY	$57.74 - $65.43 $61,377 - $69,552	1,063 Added 8.76%	13,201 $819,000
Q3 2020 Oct 16, 2020	SELL	$57.43 - $63.64 $67,020 - $74,267	-1,167 Reduced 8.77%	12,138 $732,000
Q2 2020 Jul 21, 2020	BUY	$54.82 - $64.09 $25,326 - $29,609	462 Added 3.6%	13,305 $782,000
Q1 2020 Apr 16, 2020	BUY	$46.4 - $67.43 $2,227 - $3,236	48 Added 0.38%	12,843 $716,000
Q4 2019 Jan 23, 2020	BUY	$49.21 - $64.19 $61,660 - $80,430	1,253 Added 10.86%	12,795 $821,000
Q3 2019 Oct 15, 2019	SELL	$42.77 - $50.71 $24,507 - $29,056	-573 Reduced 4.73%	11,542 $585,000
Q2 2019 Jul 18, 2019	SELL	$44.62 - $49.34 $7,094 - $7,845	-159 Reduced 1.3%	12,115 $549,000
Q1 2019 Apr 17, 2019	BUY	$45.12 - $53.8 $4,512 - $5,380	100 Added 0.82%	12,274 $586,000
Q4 2018 Jan 30, 2019	SELL	$48.76 - $63.23 $93,034 - $120,642	-1,908 Reduced 13.55%	12,174 $633,000
Q3 2018 Oct 09, 2018	BUY	$55.19 - $62.25 $16,612 - $18,737	301 Added 2.18%	14,082 $874,000
Q2 2018 Jul 16, 2018	SELL	$50.53 - $62.98 $76,047 - $94,784	-1,505 Reduced 9.85%	13,781 $763,000
Q1 2018 Apr 16, 2018	SELL	$59.92 - $68.98 $19,953 - $22,970	-333 Reduced 2.13%	15,286 $967,000
Q4 2017 Feb 07, 2018	BUY	$59.94 - $65.35 $52,447 - $57,181	875 Added 5.93%	15,619 $957,000
Q3 2017 Nov 01, 2017	BUY	$55.23 - $63.74 $814,311 - $939,782	14,744	14,744 $940,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.9 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.16 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.37 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.5 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.53 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nwam LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nwam LLC with notifications on news.

Account